LIA
CYTK icon

LS Investment Advisors’s Cytokinetics CYTK Stock Holding History

LS Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,152
Closed -$51K – 963
2020
Q2 		$51K Buy
2,152
+306
+17% +$5.74K ﹤0.01% 1166
2020
Q1 		$22K Hold
1,846
– – ﹤0.01% 1332
2019
Q4 		$20K Hold
1,846
– – ﹤0.01% 1538
2019
Q3 		$21K Hold
1,846
– – ﹤0.01% 1523
2019
Q2 		$21K Hold
1,846
– – ﹤0.01% 1525
2019
Q1 		$15K Hold
1,846
– – ﹤0.01% 1569
2018
Q4 		$12K Buy
1,846
+359
+24% +$2.63K ﹤0.01% 1580
2018
Q3 		$15K Hold
1,487
– – ﹤0.01% 1644
2018
Q2 		$12K Hold
1,487
– – ﹤0.01% 1676
2018
Q1 		$11K Hold
1,487
– – ﹤0.01% 1679
2017
Q4 		$12K Sell
1,487
-9,266
-86% -$105K ﹤0.01% 1665
2017
Q3 		$156K Buy
10,753
+2,920
+37% +$39.9K 0.01% 1033
2017
Q2 		$95K Buy
+7,833
New +$109K 0.01% 1149

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

LS Investment Advisors's CYTK Position: Q3 2020 in Review

LS Investment Advisors sold out of Cytokinetics (CYTK) in Q3 2020, closing a stake of 2,152 shares — an estimated $51K sold.

LS Investment Advisors first reported a position in CYTK in Q2 2017 and held it in 13 quarters. The position peaked at $156K in Q3 2017. 181 funds tracked by Wall St. Rank hold CYTK as of Q3 2020.

  • LS Investment Advisors reported no remaining Cytokinetics position as of Q3 2020 after selling out during the quarter.
  • LS Investment Advisors sold 2,152 Cytokinetics shares in Q3 2020, an estimated $51K.
  • LS Investment Advisors first reported a position in Cytokinetics in Q2 2017 and held it in 13 quarters.
  • LS Investment Advisors's Cytokinetics position peaked at $156K in Q3 2017.
  • 181 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2020.

Based on LS Investment Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.